← Leaderboards
Vinay Duddalwar
University Of Southern California
$1,665,647
Attributed
$4,996,941
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,996,941 · 2
By mechanism
R01$3,403,254 · 1
UG1$1,593,687 · 1
Top collaborators
- Amir Goldkorn5 shared
- Timothy J. Triche5 shared
- Anthony Boutros El-Khoueiry4 shared
- Heinz Josef Lenz4 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Caryn Lerman$95,133,528
- Mariana C Stern$2,406,912
- Christopher Alan Haiman$47,382,319
- Heinz Josef Lenz$20,123,312
- Anthony Boutros El-Khoueiry$6,814,457
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularCollectionMonitorPathway InteractionsTherapeutic TrialsSiteTumorPredicting ResponseMolecular ProfilingEvaluationResistanceResearch PersonnelResponseSamplingBloodMalignant NeoplasmsBiologicalMalignant Neoplasm Of ProstatePredictive SignatureCellsGenesParticipant EnrollmentLeadBase
Grant awards (9)
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$689,813
R01 · FY2025 · CA
NCTN - Network Lead Academic Participating Site: USC$390,493
UG1 · FY2025 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$655,325
R01 · FY2024 · CA
NCTN - Network Lead Academic Participating Site: USC$390,494
UG1 · FY2024 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$676,022
R01 · FY2023 · CA
NCTN - Network Lead Academic Participating Site: USC$381,932
UG1 · FY2023 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$676,023
R01 · FY2022 · CA
NCTN - Network Lead Academic Participating Site: USC$430,768
UG1 · FY2022 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$706,071
R01 · FY2021 · CA